Wed, Jul 23, 2014, 11:04 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Ecotality, Inc. Message Board

dottgaby 19 posts  |  Last Activity: Jul 18, 2014 4:13 PM Member since: Oct 15, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Beware Stock Manipulators

    by cookieabcd Jul 18, 2014 10:09 AM
    dottgaby dottgaby Jul 18, 2014 4:13 PM Flag

    Watch insider trading first of july......

  • dottgaby dottgaby Feb 3, 2014 6:27 AM Flag

    No Insider Buying? Check Edgar both SEC SC13 G received 01/29/14 and SEC 425 received 01/29/14

    Sentiment: Strong Buy

  • Two new forms file 425 Transcript for conference call titled, “CLI Phase 1b Topline and Cohort Data
    Presentation for conference call titled, “Critical Limb Ischemia Phase 1b Results Jan 2014.” and SC13G sabby management, very interesting....

    Sentiment: Strong Buy

  • dottgaby by dottgaby Jan 7, 2014 8:31 AM Flag

    Check Edgar news about the merger, stockholders will vote on the 13th of february

  • FROM THE SITE LAW 360 Ecotality Inc., a U.S.-backed maker of electric-car charging stations, on Thursday received approval from an Arizona bankruptcy judge to sell off its assets at an auction next month and to obtain $1.25 million in debtor-in-possession financing. U.S. Bankruptcy Judge Randolph J. Haines set an auction date for Oct. 8, and gave the green car services company leave to enter into deals with one or more stalking horse bidders by Sept. 30.San Francisco-based Ecotality plans to unload all of its assets at the sale, including equipment, machinery, inventory, supplies, real estate, software and intellectual property. Nissan North America Inc. has agreed to be Ecotality’s DIP lender.

  • dottgaby by dottgaby Aug 14, 2013 6:24 PM Flag

    Obama in 2011 promised 1.000.000 electric cars by 2015. He failed, so how can the doe pretend that Ecotality go to bankrupt if Obama did not allow industries making cars?...Without cars Ecotality cannot earn money.....this is not fair

  • dottgaby by dottgaby Jun 27, 2013 5:24 AM Flag

    KEA to Grow Presence of Electric Vehicle Charging Stations with Units at 8 More Locations, Extending Reach beyond the Western U.S.
    Print Share

    CONSHOHOCKEN, Pa., Jun 27, 2013 (BUSINESS WIRE) -- IKEA, the world's leading home furnishings retailer, today announced it extended its successful partnership with ECOtality, Inc. (NASDAQ:ECTY), a leader in clean electric transportation and storage technologies, with plans to add 24 Blink(R) electric vehicle charging stations across eight more locations in the United States.

    The newly designated sites include seven stores in Illinois, Georgia, Pennsylvania and Texas, as well as the U.S. corporate office. It is expected that installation can begin next month with completion by end of summer 2013. Installation of these units will bring the total number of Blink charging stations at IKEA locations to 55. (Two years ago, IKEA installed a combined 31 units at nine Western U.S. stores in Arizona, California, Oregon, and Washington.)

    "We are fortunate to be able to expand this relationship with ECOtality, bringing EV charging stations to more IKEA locations across the U.S. since IKEA stores are typically visible and accessible from key points within a local metropolitan area," said Mike Ward, IKEA U.S. president. "Increasing access to EV charging stations advances our goal of helping coworkers and customers - as well as members of the communities in which we operate - live more sustainable lives."

    "We are pleased to now have Blink charging stations in nearly half of all IKEA locations in the country," stated H. Ravi Brar, CEO of ECOtality. "IKEA is a household name well-known for their sustainability efforts, and we are proud they have chosen Blink as their EVSE provider of choice."

    The eight locations now scheduled to install EV charging stations are stores in: Atlanta, GA; Bolingbrook, IL; Conshohocken, PA; Frisco, TX; Houston, TX; Philadelphia, PA; and Schaumburg, IL. Additionally, the IKEA U.S. corporate office in Conshohocken also will have units available.

    IKEA, drawing from its Swedish heritage and respect of nature, believes it can be a good business while doing good business and aims to minimize impacts on the environment. Globally, IKEA evaluates locations regularly for conservation opportunities, integrates innovative materials into product design, works to maintain sustainable resources, and flat-packs goods for efficient distribution. Specific U.S. sustainable efforts include: recycling waste material; incorporating environmental measures into the actual buildings with energy-efficient HVAC and lighting systems, recycled construction materials, skylights in warehouse areas, and water-conserving restrooms; and operationally, eliminating plastic bags from the check-out process, phasing-out the sale of incandescent light bulbs, facilitating recycling of customers' compact fluorescent bulbs, and by 2016 selling and using only L.E.D. bulbs. IKEA also has installed solar panels atop nearly 90% of its US locations.

    Since its 1943 founding in Sweden, IKEA has offered home furnishings of good design and function at low prices so the majority of people can afford them. There are currently more than 340 IKEA stores in 41 countries, including 38 in the U.S. IKEA incorporates sustainability into day-to-day business and supports initiatives that benefit children and the environment

    Sentiment: Strong Buy

  • Reply to

    Some shari's restaurants

    by guyinvestor Jun 23, 2013 8:55 PM
    dottgaby dottgaby Jun 24, 2013 11:27 AM Flag

    Ikea, Best Buy, Kohls, Macys are already ECTY customers

  • dottgaby by dottgaby Jun 14, 2013 5:40 AM Flag

    ECOTALITY makes electric car charging stations and are partnered with Ikea, Best Buy, Kohls, Macys, you can charge now your electric battery on the go while you are shopping. TESLA FLIED TO THE MOON IN FEW MONTHS AND this tell you everything, about electric vehicles and electric vehicle components and car charging station.

  • dottgaby by dottgaby Jun 6, 2013 12:34 PM Flag

    http://seekingalpha.com/article/1456761-5-reasons-hydrogenics-could-triple

    Sentiment: Strong Buy

  • dottgaby by dottgaby Jun 25, 2002 10:57 AM Flag

    UPGRADE TO THE NEW VERSION,IT IS BETTER

  • dottgaby by dottgaby Apr 2, 2002 1:56 PM Flag

    Venture capital

  • dottgaby by dottgaby Mar 1, 2002 12:25 PM Flag

    Our fourth-quarter results were driven by strong customer demand for our products...In the past year, Sorrento has reached a number of significant milestones, including the release of an expanded product line in its transport and access segments," Dixon says.

    The company is in the final stages of development and testing of its TeraMAN network management platform and its TeraMatrix optical routing switch platform.

    In spite of a perceived slowdown in networking expenditures, the company continues to see strong demand for its GigaMux and EPC products from existing customers such as Deutsche Telekom [DT], Cox Communications [COX], United Pan-Europe Communications [UPCOY]and AT&T Broadband Network Solutions [T], says Dixon.

    Sorrento has begun commercial shipments of its 10 Gbps transponders supporting OC-192 and 10 Gbps ethernet.

    "We recognize the hesitation in the marketplace, the pause in available capital and the pondering over what the economy will look like," states Dixon. "But we are still seeing sales growth, adding customers, shipping larger-dollar amounts and more sophisticated equipment. Our business of enabling capital that has already been invested gives us relief from the recent slowdown in telecom spending," he says.

  • dottgaby by dottgaby Dec 6, 2001 2:05 PM Flag

    <EOM>

  • dottgaby by dottgaby Oct 15, 2001 10:56 AM Flag

    NEW YORK, Oct. 12, 2001 -- SIGA Technologies, Inc. (NASDAQ: SIGA) and (FRANKFURT: SGW 919 473), a biopharmaceutical company focusing on antibiotics and vaccines directed at bacterial infections, announced today the receipt of $2,000,000 from a private placement of 666,666 shares of common stock and warrants to purchase 333,333 shares of common stock.

    The common stock was placed at a fixed price of $3.00 per share and yielded net proceeds of approximately $1,850,000 to the company. The warrants are exercisable at $3.60 per share, a premium to the closing price of the common stock at the time the transaction was completed.

    "The closing of this placement significantly strengthens SIGA's financial foundation," stated Donald G. Drapkin, Chairman of SIGA Technologies, Inc. and Vice Chairman of McAndrew & Forbes Holdings Inc. "The proceeds from this placement will provide SIGA with the funds necessary to continue the development of its antibiotic and vaccine programs, and more importantly, this placement will provide SIGA with the funds necessary to expand and accelerate its programs to develop technology and product applications for use in defending against biological terrorism."

    The sale of common stock and warrants to purchase common stock was placed by the Shemano Group, an institutional brokerage firm in San Francisco. Gary Shemano stated, "We invest in people and we share Donald Drapkin's vision for SIGA."

    SIGA is identifying and developing novel anti-infective agents based on its pioneering research in the field of bacterial surface proteins, structures used by bacteria to initiate and maintain an infection. Drug candidates that interfere with surface protein expression are expected to be effective against a wide range of disease-causing bacteria, including antibiotic resistant bacteria, by blocking the attachment of bacteria to human tissue, the first step in the infection process. By comparison, antibiotics available today act by interfering with either the structure of the metabolism of a bacterial cell, affecting its ability to survive and to reproduce. No currently available antibiotics target the attachment of a bacterium to its target tissue. Once prevented from attaching to and colonizing human tissue, bacteria are readily cleared by the body's immune system.

    This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding the efficacy and intended utilization of SIGA's technologies under development, are not guarantees of future performance. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors which may cause such differences include the risk that potential products that appeared promising in early research or clinical trials to SIGA or its collaborators do not demonstrate efficacy or safety in subsequent pre-clinical or clinical trials, and the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market products tested in such trials.

    More detailed information about SIGA and the factors discussed above is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2000, and in other documents that SIGA has filed with the U.S. Securities and Exchange Commission. Investors and security holders are urged to read those documents free of charge at the Commission's web site at www.sec.gov. Those documents may also be obtained free of charge from SIGA. SIGA does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

  • dottgaby by dottgaby Oct 15, 2001 10:54 AM Flag

    -- SIGA Technologies, Inc. (NASDAQ: SIGA) and (FRANKFURT: SGW 919 473), a biopharmaceutical company focusing on antibiotics and vaccines directed at bacterial infections, announced today the receipt of $2,000,000 from a private placement of 666,666 shares of common stock and warrants to purchase 333,333 shares of common stock.

    The common stock was placed at a fixed price of $3.00 per share and yielded net proceeds of approximately $1,850,000 to the company. The warrants are exercisable at $3.60 per share, a premium to the closing price of the common stock at the time the transaction was completed.

    "The closing of this placement significantly strengthens SIGA's financial foundation," stated Donald G. Drapkin, Chairman of SIGA Technologies, Inc. and Vice Chairman of McAndrew & Forbes Holdings Inc. "The proceeds from this placement will provide SIGA with the funds necessary to continue the development of its antibiotic and vaccine programs, and more importantly, this placement will provide SIGA with the funds necessary to expand and accelerate its programs to develop technology and product applications for use in defending against biological terrorism."

    The sale of common stock and warrants to purchase common stock was placed by the Shemano Group, an institutional brokerage firm in San Francisco. Gary Shemano stated, "We invest in people and we share Donald Drapkin's vision for SIGA."

    SIGA is identifying and developing novel anti-infective agents based on its pioneering research in the field of bacterial surface proteins, structures used by bacteria to initiate and maintain an infection. Drug candidates that interfere with surface protein expression are expected to be effective against a wide range of disease-causing bacteria, including antibiotic resistant bacteria, by blocking the attachment of bacteria to human tissue, the first step in the infection process. By comparison, antibiotics available today act by interfering with either the structure of the metabolism of a bacterial cell, affecting its ability to survive and to reproduce. No currently available antibiotics target the attachment of a bacterium to its target tissue. Once prevented from attaching to and colonizing human tissue, bacteria are readily cleared by the body's immune system.

    This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding the efficacy and intended utilization of SIGA's technologies under development, are not guarantees of future performance. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors which may cause such differences include the risk that potential products that appeared promising in early research or clinical trials to SIGA or its collaborators do not demonstrate efficacy or safety in subsequent pre-clinical or clinical trials, and the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market products tested in such trials.

    More detailed information about SIGA and the factors discussed above is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2000, and in other documents that SIGA has filed with the U.S. Securities and Exchange Commission. Investors and security holders are urged to read those documents free of charge at the Commission's web site at www.sec.gov. Those documents may also be obtained free of charge from SIGA. SIGA does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

  • dottgaby by dottgaby Oct 15, 2001 10:51 AM Flag

    NEW YORK, -- SIGA Technologies, Inc. (NASDAQ: SIGA) and (FRANKFURT: SGW 919 473), a biopharmaceutical company focusing on antibiotics and vaccines directed at bacterial infections, announced today the receipt of $2,000,000 from a private placement of 666,666 shares of common stock and warrants to purchase 333,333 shares of common stock.

    The common stock was placed at a fixed price of $3.00 per share and yielded net proceeds of approximately $1,850,000 to the company. The warrants are exercisable at $3.60 per share, a premium to the closing price of the common stock at the time the transaction was completed.

    "The closing of this placement significantly strengthens SIGA's financial foundation," stated Donald G. Drapkin, Chairman of SIGA Technologies, Inc. and Vice Chairman of McAndrew & Forbes Holdings Inc. "The proceeds from this placement will provide SIGA with the funds necessary to continue the development of its antibiotic and vaccine programs, and more importantly, this placement will provide SIGA with the funds necessary to expand and accelerate its programs to develop technology and product applications for use in defending against biological terrorism."

    The sale of common stock and warrants to purchase common stock was placed by the Shemano Group, an institutional brokerage firm in San Francisco. Gary Shemano stated, "We invest in people and we share Donald Drapkin's vision for SIGA."

    SIGA is identifying and developing novel anti-infective agents based on its pioneering research in the field of bacterial surface proteins, structures used by bacteria to initiate and maintain an infection. Drug candidates that interfere with surface protein expression are expected to be effective against a wide range of disease-causing bacteria, including antibiotic resistant bacteria, by blocking the attachment of bacteria to human tissue, the first step in the infection process. By comparison, antibiotics available today act by interfering with either the structure of the metabolism of a bacterial cell, affecting its ability to survive and to reproduce. No currently available antibiotics target the attachment of a bacterium to its target tissue. Once prevented from attaching to and colonizing human tissue, bacteria are readily cleared by the body's immune system.

    This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding the efficacy and intended utilization of SIGA's technologies under development, are not guarantees of future performance. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors which may cause such differences include the risk that potential products that appeared promising in early research or clinical trials to SIGA or its collaborators do not demonstrate efficacy or safety in subsequent pre-clinical or clinical trials, and the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market products tested in such trials.

    More detailed information about SIGA and the factors discussed above is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2000, and in other documents that SIGA has filed with the U.S. Securities and Exchange Commission. Investors and security holders are urged to read those documents free of charge at the Commission's web site at www.sec.gov. Those documents may also be obtained free of charge from SIGA. SIGA does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

  • dottgaby by dottgaby Oct 15, 2001 10:47 AM Flag

    NEW YORK, Oct. 12, 2001 -- SIGA Technologies, Inc. (NASDAQ: SIGA) and (FRANKFURT: SGW 919 473), a biopharmaceutical company focusing on antibiotics and vaccines directed at bacterial infections, announced today the receipt of $2,000,000 from a private placement of 666,666 shares of common stock and warrants to purchase 333,333 shares of common stock.

    The common stock was placed at a fixed price of $3.00 per share and yielded net proceeds of approximately $1,850,000 to the company. The warrants are exercisable at $3.60 per share, a premium to the closing price of the common stock at the time the transaction was completed.

    "The closing of this placement significantly strengthens SIGA's financial foundation," stated Donald G. Drapkin, Chairman of SIGA Technologies, Inc. and Vice Chairman of McAndrew & Forbes Holdings Inc. "The proceeds from this placement will provide SIGA with the funds necessary to continue the development of its antibiotic and vaccine programs, and more importantly, this placement will provide SIGA with the funds necessary to expand and accelerate its programs to develop technology and product applications for use in defending against biological terrorism."

    The sale of common stock and warrants to purchase common stock was placed by the Shemano Group, an institutional brokerage firm in San Francisco. Gary Shemano stated, "We invest in people and we share Donald Drapkin's vision for SIGA."

    SIGA is identifying and developing novel anti-infective agents based on its pioneering research in the field of bacterial surface proteins, structures used by bacteria to initiate and maintain an infection. Drug candidates that interfere with surface protein expression are expected to be effective against a wide range of disease-causing bacteria, including antibiotic resistant bacteria, by blocking the attachment of bacteria to human tissue, the first step in the infection process. By comparison, antibiotics available today act by interfering with either the structure of the metabolism of a bacterial cell, affecting its ability to survive and to reproduce. No currently available antibiotics target the attachment of a bacterium to its target tissue. Once prevented from attaching to and colonizing human tissue, bacteria are readily cleared by the body's immune system.

    This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding the efficacy and intended utilization of SIGA's technologies under development, are not guarantees of future performance. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors which may cause such differences include the risk that potential products that appeared promising in early research or clinical trials to SIGA or its collaborators do not demonstrate efficacy or safety in subsequent pre-clinical or clinical trials, and the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market products tested in such trials.

    More detailed information about SIGA and the factors discussed above is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2000, and in other documents that SIGA has filed with the U.S. Securities and Exchange Commission. Investors and security holders are urged to read those documents free of charge at the Commission's web site at www.sec.gov. Those documents may also be obtained free of charge from SIGA. SIGA does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

ECTY
0.1240.000(0.00%)Sep 26 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.